Evaluation of the efficacy and tolerability of alendronate versus denosumab in kidney transplant patients with reduced bone mineral density.
alendronate
bone mineral density
denosumab
osteoporosis
renal transplantation
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
14
04
2023
received:
18
01
2023
accepted:
18
04
2023
medline:
14
9
2023
pubmed:
16
6
2023
entrez:
16
6
2023
Statut:
ppublish
Résumé
To compare the effect of denosumab and alendronate on bone mineral density (BMD) in renal transplant recipients (RTRs) with low bone mass. Patients were randomized to receive either denosumab subcutaneously (60 mg/6 months), oral alendronate (70 mg/week), or no treatment for 1 year. The three groups were prescribed daily calcium and vitamin D. Primary outcome was BMD assessed at lumbar spine, hip, and radius and measured by dual-energy X-ray absorptiometry (DEXA) at baseline and after 6 and 12 months. Adverse events and laboratory assessments (calcium, phosphate, vitamin D, renal functions, and intact parathyroid hormone) were monitored for all patients. Quality of life was assessed at baseline and after 6 and 12 months for all patients. Ninety RTRs were included in the study (30 in each group). Baseline clinical characteristics and BMD values were comparable in the three groups. After 12 months, lumbar spine T-score of patients treated with denosumab and alendronate showed a median increase of 0.5 [95% confidence interval (CI): 0.4-0.6] and 0.5 (95% CI: 0.4-0.8), respectively, and patients in the control group showed a decrease of -0.2 (95% CI: -0.3 to -0.1), p < 0.001. Denosumab and alendronate showed a significant comparable gain in T-scores at hip and radius versus a significant decrease in the control group. Adverse events and laboratory values were similar in the three groups. Both treatments resulted in comparable significant improvement in physical functioning, physical role limitations, vitality, and pain scores. Denosumab and alendronate showed comparable efficacy in improving BMD at all measured skeletal sites and were safe and well-tolerated, with no serious adverse effects reported in RTRs with low bone mass. The study was registered on ClinicalTrials.gov, number NCT04169698.
Substances chimiques
Alendronate
X1J18R4W8P
Denosumab
4EQZ6YO2HI
Bone Density Conservation Agents
0
Calcium
SY7Q814VUP
Vitamin D
1406-16-2
Banques de données
ClinicalTrials.gov
['NCT04169698']
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
904-912Informations de copyright
© 2023 Pharmacotherapy Publications, Inc.
Références
Trabulus S, Altiparmak MR, Apaydin S, Serdengecti K, Sariyar M, et al. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. Transplant Proc. 2008;40(1):160-166.
Bouquegneau A, Salam S, Delanaye P, Eastell R, Khwaja A, et al. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(7):1282-1296.
Brandenburg VM, Politt D, Ketteler M, et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation. 2004;77(10):1566-1571.
Alfieri C, Binda V, Malvica S, et al. Bone effect and safety of one-year denosumab therapy in a cohort of renal transplanted patients: an observational monocentric study. J Clin Med. 2021;10(9):1989.
Heimgartner N, Graf N, Frey D, et al. Predictive power of bone turnover biomarkers to estimate bone mineral density after kidney transplantation with or without denosumab: a post hoc analysis of the POSTOP study. Kidney Blood Press Res. 2020;45(5):758-767.
McKee H, Ioannidis G, Lau A, et al. Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients. Osteoporos Int. 2020;31(5):973-980.
Thongprayoon C, Acharya P, Aeddula NR, et al. Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. Arch Osteoporos. 2019;14(35):1-13.
Wheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7(1):1-59.
Yang Y, Qiu S, Tang X, et al. Efficacy and safety of different bisphosphonates for bone loss prevention in kidney transplant recipients: a network meta-analysis of randomized controlled trials. Chin Med J (Engl). 2018;131(7):818-828.
Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE, et al. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant. 2016;30(9):1090-1096.
Diab DL, Watts NB, Miller PD, et al. Bisphosphonates pharmacology and use in the treatment of osteoporosis. Marcus and Feldman's osteoporosis. Elsevier; 2021:1721-1736.
Kobel C, Frey D, Graf N, Wüthrich RP, Bonani M. Follow-up of bone mineral density changes in de novo kidney transplant recipients treated with two doses of the receptor activator of nuclear factor κB ligand inhibitor Denosumab. Kidney Blood Press Res. 2019;44:1285-1293.
Park S, Jeong TD. Estimated glomerular filtration rates show minor but significant differences between the single and subgroup creatinine-based chronic kidney disease epidemiology collaboration equations. Ann Lab Med. 2019;39(2):205-208.
Ware JE Jr. SF-36 health survey update. Spine. 2000;25(24): 3130-3139.
Bunevicius A. Reliability and validity of the SF-36 health survey questionnaire in patients with brain tumors: a cross-sectional study. Health Qual Life Outcomes. 2017;15(1):1-7.
Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol (Lausanne). 2018;9:1-8.
Bonani M, Frey D, Brockmann J, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882-1891.
Lip A, Warias A, Shamseddin MK, Thomson B, Wijeratne DT, et al. Effect of bisphosphonates on bone health in adult renal transplant patients: beyond the first year posttransplant-a systematic review and meta-analysis. Can J Kidney Heal Dis. 2019;6:1-17.
Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153-161.
Iseri K, Iyoda M, Watanabe M, et al. The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: a randomized, controlled trial. PLoS One. 2018;13(3):1-12.
Kendler DL, McClung MR, Freemantle N, et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int. 2011;22(6):1725-1735.
Freemantle N, Satram-Hoang S, Tang ET, et al. Final results of the DAPS (denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317-326.
Malluche HH, Monier-Faugere MC, Herberth J. Bone disease after renal transplantation. Nat Rev Nephrol. 2010;6(1):32-40.
Marques IDB, Araújo MJCLN, Graciolli FG, et al. A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol. 2019;30(2):355-365.
Giannini S, D'Angelo A, Carraro G, et al. Alendronate prevents further bone loss in renal transplant recipients. J Bone Miner Res. 2001;16(11):2111-2117.
Cruz DN, Brickel HM, Wysolmerski JJ, et al. Treatment of osteoporosis and osteopenia in long-term renal transplant patients with alendronate. Am J Transplant. 2002;2(1):62-67.
Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN, et al. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation. 2003;76(10):1498-1502.
Shahbazian H, Mowla K, Shahbazian HB, Peydayesh B, Ehsanpour A, et al. Efficacy and safety of alendronate in the prevention of bone loss in renal transplant recipients. Indian J Nephrol. 2007;17(2):61.
Block GA, Bone HG, Fang L, Lee E, Padhi D, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res. 2012;27(7):1471-1479.
Balaska A, Pistolas D, Koukoulaki M, et al. Changes in health-related quality of life in Greek adult patients two years after successful renal transplantation. BANTAO J. 2016;14(1):30-33.